IQVIA conference posters on EU HTA

Solutions Real World Evidence Health Economics and Value EU HTA Solutions IQVIA conference posters on EU HTA

Are we there yet? Mapping member state readiness for local implementation of the EU Health Technology Assessment (HTA) Regulation

Savvas Dimiou, Edel Falla, Sian Tanner, Ansa Ibok, Valentine Berthet, Doreen Bonduelle, Daniel Callejo, Tijl De Celle, Brittany du Preez, Maaike Janssen, Maria Kalogeropoulou, Agnieszka Koppolu, Robert Krüger, Gloria Lombardi, Pauline Pasman, Anke van Engen, Max van Wijk, Jacek Wieczorek

IQVIA conference posters on EU HTA

Are we there yet? Mapping member state readiness for local implementation of the EU Health Technology Assessment (HTA) Regulation

Challenges at the interface between EU-HTA (JCA) and national HTA in Germany (AMNOG): Expected limitations to synergy effects and implications for AMNOG dossier preparation

External controls: What does it take to get real?

Get JCA-ready: Mastering PROs for market access success

Guidance for real-world evidence generation for the Joint Clinical Assessment process and its implications for country-specific HTA body acceptability

Lifecycle stage-specific prioritization of Joint Clinical Assessment PICOs: Balancing access potential, feasibility, and likelihood

Optimizing PICO scoping in EU HTA: Lessons from an HTA Coordination Group PICO exercise in advanced NSCLC to inform future best practice

Overall Survival adjusted for subsequent treatments: A review of health technology assessments

Paving the path to success for Joint Clinical Assessments – one asset at a time

Readying for the second wave: What, when and how must orphan medicine manufacturers prepare for EU HTAR?

Simulating PICOs to predict evidence requirement implications of the EU Joint Clinical Assessment: Learnings from 24 case studies

The Evolving Horizon of Oncology: Predicting the Impact of the EU HTA Regulation for 2026-2029

Transparency tested: Conflict of interest in EU HTA

ISPOR EU 2024

Comparison of the guidelines for quantitative evidence synthesis in the European Union (EU) joint clinical assessment (JCA) of medicinal products to current methods for health technology assessment (HTA) in Germany

Comparison of the joint clinical assessment (JCA) dossier with the German Medicines Market Reorganization Act (AMNOG) dossier – what content remains to be presented in the AMNOG dossier after implementation of JCA?

EU joint clinical assessment (JCA): Uncertain impact on German AMNOG timelines and potential delays

Could the European joint clinical assessment (EU JCA) delay access to new medicines in France?

From clinical assessment to drug reimbursement in Spain: Current timelines and potential impact from the joint clinical assessment

Potential impact of joint clinical assessment (JCA) on health technology assessment timelines in Ireland

When timelines collide: How EMA regulatory milestones can impact the JCA process, and implications for manufacturers and member states

The butterfly effect: Impact of EU HTA on price evolution via international reference pricing

A blueprint for success: The importance of multi-stakeholder alignment for EU health technology assessment (HTA)

Indirect treatment comparisons with full individual patient data for joint clinical assessment: Lessons learned and best practices from a review of HTA appraisals

Predicting PICOs to prepare for joint clinical assessment – learnings from 19 case studies

Vaccines and EU HTA: Exploring misalignments between joint clinical assessment requirements and a hypothetical vaccine evidence package

A comparison of the acceptability of evidence in the new joint clinical assessment and nine European Union countries

Predicting the evidence requirement implications of the European Union (EU) joint clinical assessment (JCA) by conducting a Population, Comparator, Intervention, Outcome (PICO) simulation for two anticancer investigational medicinal products (IMPs)

The horizon of oncology: Estimating the impact of new EU Regulation on health technology assessment for 2025-2028

Including patient experience data in the HTA decision-making framework: A proposal based on HTA-stakeholder interviews

Use of artificial intelligence and machine learning (AI/ML) in systematic literature reviews (SLR): Review of state-of-the-art health technology assessment and future directions

Do we need to adapt our health technology assessment (HTA) systematic literature review (SLR) methods to comply with the new Joint Clinical Assessment (JCA) SLR?